The herpes zoster therapeutics market is fragmented, and the vendors are deploying growth strategies such as focusing on expanding their business activities in developed and rapidly emerging markets by launching products to compete in the market, according to a report from Technavio.
The herpes zoster therapeutics market size is expected to grow by $4.51Bn from 2021 to 2026. Moreover, the growth momentum of the market will accelerate at a CAGR of 14.67% during the forecast period.
The increased incidence of herpes zoster is driving the herpes zoster therapeutics market growth. Exposure to ultraviolet radiation may suppress cell-mediated immunity, which can increase the incidence of herpes zoster. In addition, factors such as stress are expected to weaken the immune system of a person, which increases the risk of getting herpes zoster and other infectious diseases. Thus, the rise in the incidence of herpes zoster across the world is expected to drive the growth of the market during the forecast period.
The weak pipeline for herpes zoster therapeutics is challenging the growth of the herpes zoster therapeutics market. The acceptance of vaccines varies across countries. One of the main reasons includes the fear of an upward shift in the peak of the age of the infection. In addition, universal childhood varicella vaccination programs are not compulsory in most countries. Thus, the realizable market for vaccines may remain low, which makes it less attractive for vaccine manufacturers.